HUE044374T2 - Módszerek rák klinikai kimenetelének elõrejelzésére - Google Patents

Módszerek rák klinikai kimenetelének elõrejelzésére

Info

Publication number
HUE044374T2
HUE044374T2 HUE10832289A HUE044374T2 HU E044374 T2 HUE044374 T2 HU E044374T2 HU E10832289 A HUE10832289 A HU E10832289A HU E044374 T2 HUE044374 T2 HU E044374T2
Authority
HU
Hungary
Prior art keywords
cancer
methods
clinical outcome
predict clinical
predict
Prior art date
Application number
Other languages
English (en)
Inventor
Joffre B Baker
Maureen T Cronin
Francois Collin
mei-lan Liu
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of HUE044374T2 publication Critical patent/HUE044374T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HUE10832289 2009-11-23 2010-11-19 Módszerek rák klinikai kimenetelének elõrejelzésére HUE044374T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26376309P 2009-11-23 2009-11-23

Publications (1)

Publication Number Publication Date
HUE044374T2 true HUE044374T2 (hu) 2019-10-28

Family

ID=44060376

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10832289 HUE044374T2 (hu) 2009-11-23 2010-11-19 Módszerek rák klinikai kimenetelének elõrejelzésére

Country Status (13)

Country Link
US (4) US20110123990A1 (hu)
EP (4) EP3556867A1 (hu)
JP (7) JP5964752B2 (hu)
AU (1) AU2010321829B2 (hu)
CA (2) CA3043089A1 (hu)
DK (1) DK2504451T3 (hu)
ES (1) ES2735993T3 (hu)
HU (1) HUE044374T2 (hu)
IL (5) IL219051A (hu)
MX (3) MX391499B (hu)
NZ (1) NZ599194A (hu)
PL (1) PL2504451T3 (hu)
WO (1) WO2011063274A2 (hu)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
JP5020088B2 (ja) * 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
RU2011102743A (ru) * 2008-06-26 2012-08-10 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
CA3043089A1 (en) * 2009-11-23 2011-05-26 Genomic Health, Inc. Methods to predict clinical outcome of cancer
EP3178944B1 (en) 2010-01-11 2019-05-15 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
MX338883B (es) 2010-07-27 2016-05-04 Genomic Health Inc Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
EP2691547A4 (en) * 2011-03-26 2015-01-14 Univ Oregon Health & Science GENE EXPRESSION PREDICTORS FOR CANCER PROSPECTS
CA2840472A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
WO2013006495A2 (en) * 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
JP2014523589A (ja) 2011-07-13 2014-09-11 ザ マルチプル ミエローマ リサーチ ファウンデーション， インコーポレイテッド データ収集及び配信のための方法
KR20140057331A (ko) * 2011-08-16 2014-05-12 온코사이트 코포레이션 유방암의 치료 및 진단을 위한 방법 및 조성물
EP2776830B1 (en) * 2011-11-08 2018-05-09 Genomic Health, Inc. Method of predicting breast cancer prognosis
JP5805518B2 (ja) 2011-12-21 2015-11-04 株式会社島津製作所 マルチプレックス大腸がんマーカーパネル
US8725426B2 (en) * 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
GB201206323D0 (en) * 2012-04-10 2012-05-23 Immunovia Ab Methods and arrays for use in the same
WO2013159099A2 (en) * 2012-04-20 2013-10-24 Memorial Sloan-Kettering Cancer Center Gene expression profiles associated with metastatic breast cancer
WO2014055398A1 (en) * 2012-10-05 2014-04-10 Siemens Healthcare Diagnostics Inc. Method for detecting an increased risk or incidence of colorectal cancer
WO2014078700A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
ES2859645T3 (es) 2013-03-14 2021-10-04 Mayo Found Medical Education & Res Detección de neoplasia
KR101672531B1 (ko) * 2013-04-18 2016-11-17 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도
JP2016521979A (ja) 2013-05-30 2016-07-28 ジェノミック ヘルス， インコーポレイテッド 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
WO2014195032A1 (en) * 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
US20170073763A1 (en) * 2014-03-12 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Methods and Compositions for Assessing Patients with Non-small Cell Lung Cancer
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
WO2016092299A1 (en) * 2014-12-09 2016-06-16 Medical Research Council Methods and kits for predicting the response to therapy of cancer
CN107532124B (zh) 2015-03-27 2022-08-09 精密科学公司 检测食管疾病
CN108138235B (zh) 2015-08-31 2022-04-15 梅约医药教育及研究基金会 检测胃肿瘤
AU2016343937B2 (en) 2015-10-30 2023-01-19 Exact Sciences Corporation Multiplex amplification detection assay and isolation and detection of DNA from plasma
WO2017106790A1 (en) 2015-12-18 2017-06-22 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
CN110225984A (zh) * 2016-09-07 2019-09-10 科技研究局 鉴别癌症风险的方法和治疗选择
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
KR102892245B1 (ko) 2017-01-27 2025-11-27 이그젝트 싸이언스 디블롭먼트 컴패니, 엘엘씨 메틸화된 dna 분석에 의한 결장 신조직형성의 검출
WO2018212192A1 (ja) * 2017-05-18 2018-11-22 京都府公立大学法人 癌の予後及び／又は転移可能性を評価する方法及びマーカー
US12275994B2 (en) * 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers
EP3513280A4 (en) 2017-11-13 2020-07-22 The Multiple Myeloma Research Foundation, Inc. INTEGRATED, MOLECULAR, OMIC, IMMUNOTHERAPY, METABOLIC, EPIGENETIC AND CLINICAL DATABASE
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
AU2019230200A1 (en) * 2018-03-08 2020-10-29 University Of Notre Dame Du Lac Systems and methods for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon
JP7199045B2 (ja) * 2018-04-13 2023-01-05 国立大学法人大阪大学 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム
WO2020059850A1 (ja) * 2018-09-21 2020-03-26 国立大学法人東京大学 がんの予後判定方法
JP2019032334A (ja) * 2018-10-03 2019-02-28 イムノヴィア・アクチエボラーグ 乳癌関連の疾患状態を決定する方法およびこの方法における使用のためのアレイ
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
WO2020118274A1 (en) * 2018-12-08 2020-06-11 Pfs Genomics, Inc. Transcriptomic profiling for prognosis of breast cancer
CN113785076B (zh) * 2019-05-03 2024-06-11 株式会社递希真 预测癌症预后的方法及其组合物
CN111235270B (zh) * 2019-08-29 2022-04-29 北京臻知医学科技有限责任公司 一种基于高通量测序法的肿瘤抗原表达检测引物及试剂盒
US12165747B2 (en) * 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
US20240117444A1 (en) * 2021-02-12 2024-04-11 Mammogen, Inc. Biomarkers for the diagnosis of breast cancer
WO2022192128A2 (en) * 2021-03-08 2022-09-15 Castle Biosciences, Inc. Determining prognosis and treatment based on clinical-pathologic factors and continuous multigene-expression profile scores
CN117116345B (zh) * 2023-07-24 2025-09-16 中国人民解放军军事科学院军事医学研究院 一种基于基因调控网络构建患者生存网络的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
JP2005500832A (ja) * 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド 乳癌患者の診断および予後
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
CA2992643C (en) * 2002-03-13 2019-06-18 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040067234A1 (en) * 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US7526387B2 (en) * 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US8019552B2 (en) * 2004-03-05 2011-09-13 The Netherlands Cancer Institute Classification of breast cancer patients using a combination of clinical criteria and informative genesets
WO2006037485A2 (en) * 2004-09-30 2006-04-13 Bayer Healthcare Ag Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
US20080193938A1 (en) * 2005-04-01 2008-08-14 Yu Kun Materials And Methods Relating To Breast Cancer Classification
WO2006133460A2 (en) * 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
TWI304443B (en) * 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
WO2007123772A2 (en) * 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
US20100234292A1 (en) * 2007-04-16 2010-09-16 Ipsogen Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
WO2009095319A1 (en) * 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
WO2009132928A2 (en) * 2008-05-02 2009-11-05 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
DK2568053T3 (da) * 2008-05-12 2014-07-21 Genomic Health Inc Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder
CA3043089A1 (en) * 2009-11-23 2011-05-26 Genomic Health, Inc. Methods to predict clinical outcome of cancer

Also Published As

Publication number Publication date
MX2012005822A (es) 2012-06-19
EP2504451A4 (en) 2016-07-06
CA3043089A1 (en) 2011-05-26
US20190241967A1 (en) 2019-08-08
AU2010321829A1 (en) 2012-05-03
JP2022169647A (ja) 2022-11-09
IL257063B (en) 2019-01-31
JP2016214245A (ja) 2016-12-22
IL276487B (en) 2022-03-01
JP7823012B2 (ja) 2026-03-03
EP3739060A1 (en) 2020-11-18
MX2019003811A (es) 2019-08-05
IL276487A (en) 2020-09-30
MX391499B (es) 2025-03-21
IL219051A (en) 2016-12-29
MX337650B (es) 2016-03-14
IL264072A (en) 2019-02-28
JP2024037948A (ja) 2024-03-19
US20170211154A1 (en) 2017-07-27
CA2776751A1 (en) 2011-05-26
AU2010321829B2 (en) 2015-07-30
ES2735993T3 (es) 2019-12-23
DK2504451T3 (da) 2019-08-05
EP3556867A1 (en) 2019-10-23
WO2011063274A3 (en) 2014-03-27
IL264072B (en) 2020-08-31
EP4350001A3 (en) 2024-06-19
IL219051A0 (en) 2012-06-28
JP5964752B2 (ja) 2016-08-03
MX363817B (es) 2019-04-04
EP4350001A2 (en) 2024-04-10
JP2022166064A (ja) 2022-11-01
EP2504451A2 (en) 2012-10-03
IL249159A0 (en) 2017-01-31
JP2013514058A (ja) 2013-04-25
JP2021058207A (ja) 2021-04-15
US20210062275A1 (en) 2021-03-04
NZ599194A (en) 2014-07-25
PL2504451T3 (pl) 2019-09-30
EP2504451B1 (en) 2019-06-05
US20110123990A1 (en) 2011-05-26
JP7042717B2 (ja) 2022-03-28
WO2011063274A2 (en) 2011-05-26
CA2776751C (en) 2019-07-02
JP2018196385A (ja) 2018-12-13

Similar Documents

Publication Publication Date Title
IL276487B (en) Methods for predicting clinical outcome of cancer
IL276362A (en) Cancer treatment methods
IL251635A0 (en) A method for using gene expression to determine the likelihood of clinical outcome in kidney cancer
IL218575A0 (en) Treatment of cancer
ZA201206019B (en) Methods for predicting response of triple-negative breast cancer to therapy
IL251403A0 (en) A method for using gene expression to determine the prognosis of prostate cancer
HRP20140140T1 (en) Gene expression profiles to predict breast cancer outcomes
EP2438197A4 (en) METHOD OF CANCER DETECTION
IL223189A0 (en) Methods of treatment of pancreatic cancer
ZA201208815B (en) Methods of treating bladder cancer
PT2435825E (pt) Métodos para o tratamento de doenças
EP2461814A4 (en) PROSTATE CANCER TREATMENT
SG10201508495VA (en) Combination treatment of cancer
ZA201304226B (en) Methods of treating cancer
EP2640390A4 (en) METHODS OF TREATING CANCER
IL218230A0 (en) Method of treating cancer
IL216580A0 (en) Use of anti-sparc antibodies to predict response to chemothrapy
EP2593100A4 (en) METHOD OF TREATING REFRACTORY CANCER
IL213919A0 (en) Methods to treat cancer
GB0916686D0 (en) Treatment of cancer
GB0921757D0 (en) Treatment of cancer
IL223237A0 (en) Diagnosis of cancer
GB201017354D0 (en) Treatment of cancer
GB201007977D0 (en) Treatment of cardiovascular disease
GB0906490D0 (en) Use of tetanolic for treatment of breast cancer